Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating extended-release niacin combined with laropiprant and simvastatin in primary hypercholesterolemia or mixed dyslipidemia was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypercholesterolemia

Drugs mentioned

• Extended-release Niacin (Niacin (extended-release))
• Laropiprant (laropiprant)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Primary Hypercholesterolemia, Dyslipidemia | Phase 3 | Status: TERMINATED | Results posted: 2016-12-13